3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pancreatic Neoplasms
26
Urinary Bladder Neoplasms
17
Carcinoma, Non-Small-Cell Lung
17
Lung Neoplasms
13
Ovarian Neoplasms
10
Nasopharyngeal Carcinoma
9
Biliary Tract Neoplasms
8
Non-Muscle Invasive Bladder Neoplasms
7
Neoplasm Metastasis
7
Cholangiocarcinoma
7
Lymphoma, Large B-Cell, Diffuse
6
Triple Negative Breast Neoplasms
5
Colorectal Neoplasms
5
Breast Neoplasms
5
Recurrence
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Neoplasms
4
Fallopian Tube Neoplasms
4
Endometrial Neoplasms
4
Carcinoma, Transitional Cell
4
Osteosarcoma
3
Melanoma
3
Lymphoma, Non-Hodgkin
3
Uterine Cervical Neoplasms
2
Urologic Neoplasms
2
Rectal Neoplasms
2
Lymphoma, Follicular
2
Lymphoma, B-Cell
2
Gallbladder Neoplasms
2
Colonic Neoplasms
2
Interventions
pembrolizumab
1
enfortumab vedotin
1
Radiation Dose Hypofractionation
1
Mitomycin
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Male Urogenital Diseases
×
Gemcitabine
×
30 days
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled